MYGN MYRIAD GENETICS INC
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 899923 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.6%
TTM net income YoY67.8%
TTM EPS YoY69.0%
Revenue 3-yr CAGR3.0%
Net income 3-yr CAGR—
Margins
Gross margin68.3%
Operating margin-14.3%
Net margin-16.1%
FCF margin—
EBITDA margin-10.0%
Returns
ROE-40.2%
ROA-19.3%
ROIC (approx.)-28.9%
Asset turnover1.20x
Leverage & solvency
Liabilities / assets55.8%
Debt / equity0.45x
Current ratio1.98x
Interest coverage-6.90x
Cash quality & payout
Operating cash flow / net income0.15x
Accruals ratio-16.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $824.50M | $837.60M | $753.20M | $678.40M | $690.60M |
| Cost of revenue | $247.90M | $252.20M | $236.20M | $202.00M | — |
| Gross profit | $576.60M | $585.40M | $517.00M | $476.40M | — |
| R&D expense | $106.80M | $113.40M | $88.70M | $85.40M | $81.90M |
| SG&A expense | $256.80M | $275.90M | $283.70M | $247.90M | $537.80M |
| Operating income | -$387.20M | -$123.50M | -$257.40M | -$140.60M | -$190.50M |
| Interest expense | $10.50M | $2.80M | $2.90M | $3.20M | $6.60M |
| Pretax income | -$395.10M | -$123.50M | -$262.20M | -$140.60M | -$57.10M |
| Income tax | -$29.20M | $3.80M | $1.10M | -$28.60M | -$29.90M |
| Net income | -$365.90M | -$127.30M | -$263.30M | -$112.00M | -$27.20M |
| EBITDA | -$333.50M | -$62.30M | -$195.50M | -$87.90M | -$127.70M |
| EPS (basic) | -3.95 | -1.41 | -3.18 | -1.39 | -0.35 |
| EPS (diluted) | -3.95 | -1.41 | -3.18 | -1.39 | -0.35 |
| Weighted avg. shares (diluted) | 92.60M | 90.60M | 82.80M | 80.60M | 78.00M |
| Balance sheet | |||||
| Cash & equivalents | $149.60M | $111.90M | $132.10M | $66.40M | $258.80M |
| Short-term investments | — | $0 | $8.80M | $58.00M | $81.40M |
| Receivables | $115.30M | $121.20M | $114.30M | $101.60M | $91.30M |
| Inventory | $30.60M | $27.50M | $22.00M | $20.10M | $15.30M |
| Current assets | $332.60M | $298.00M | $313.60M | $274.60M | $484.80M |
| PP&E, net | $114.00M | $117.40M | $119.00M | $83.40M | $43.50M |
| Goodwill | $51.60M | $286.30M | $287.40M | $286.80M | $239.20M |
| Intangibles | $153.40M | $262.40M | $349.50M | $379.70M | $404.10M |
| Total assets | $706.60M | $1.03B | $1.15B | $1.20B | $1.32B |
| Current liabilities | $133.80M | $164.10M | $155.90M | $137.20M | $204.30M |
| Short-term debt | — | $0 | — | — | — |
| Long-term debt | $119.90M | $39.60M | $38.50M | $0 | $0 |
| Total debt | $119.90M | $39.60M | $38.50M | $0 | $0 |
| Total liabilities | $338.60M | $326.50M | $363.30M | $312.90M | $352.90M |
| Shareholders' equity | $368.00M | $701.10M | $783.20M | $885.80M | $967.80M |
| Net debt | -$29.70M | -$72.30M | -$93.60M | -$66.40M | -$258.80M |
| Shares outstanding | 93.50M | 91.30M | 89.90M | 81.20M | 80.00M |
| Cash flow statement | |||||
| Operating cash flow | $1.80M | -$8.70M | -$110.90M | -$106.30M | $18.60M |
| Capital expenditure | — | — | — | $45.30M | $18.00M |
| Free cash flow | — | — | — | -$151.60M | $600,000 |
| Investing cash flow | -$27.40M | -$11.90M | $31.90M | -$77.50M | $274.40M |
| Financing cash flow | $64.20M | -$7.40M | $152.90M | -$8.00M | -$150.60M |
| Depreciation & amortization | $53.70M | $61.20M | $61.90M | $52.70M | $62.80M |
| Stock-based compensation | $35.20M | $49.80M | $40.70M | $38.10M | $36.30M |
| Share buybacks | — | — | — | — | $0 |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.